Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis
NCT ID: NCT00546936
Last Updated: 2009-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
30 participants
INTERVENTIONAL
2007-10-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
NCT00436553
Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
NCT00955630
Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia
NCT01968486
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
NCT00363168
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
NCT00749021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ranibizumab intravitreal injection
0.5 mg intravitreal injection of ranibizumab
ranibizumab
0.5mg ranibizumab
Photodynamic Therapy
Photodynamic therapy with Visudyne
verteporfin
Photodynamic therapy with verteporfin every 3 months for 1 year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ranibizumab
0.5mg ranibizumab
verteporfin
Photodynamic therapy with verteporfin every 3 months for 1 year
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to provide written informed consent and comply with study assessments for the full duration of the study
* Age greater than or equal to 21 years of age
* CNV lesion of than \< 5400 microns in diameter
* Best corrected visual acuity of 20/40-20/320
* Birth control therapy for females of child-bearing potential
Exclusion Criteria
* Pregnancy or lactation premenopausal women not using adequate contraception
* Prior enrollment in the study
* Any other condition that the Investigator believes would pose a significant hazard to the subject
* Participation in another simultaneous medical investigation or trial
* Participation in another trial or previous trial of ranibizumab or Avastin
* Any concurrent ocular condition in the study eye (cataract, diabetic retinopathy)that could require medical or surgical intervention or ifa allowed to progress, could likely contribute to loss of at least 2 Snellen equivalent lines of BCVA over the 12-month study period
* Previous panretinal photocoagulation
* Previous steroids or PDT in 3 months
* Previous participation in any studies of investigational drugs within 30 days preceding Day 0
* Prior participation in a Genentech ranibizumab clinical trial
* Previous treatment with intravitreally (in either eye) or intravenously administered Avastin within 3 months
* Previous use of Macugen in the study eye within 3 months
* Prior submacular surgery
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Barnes Retina Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Barnes Retina Institute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kevin J. Blinder, MD
Role: PRINCIPAL_INVESTIGATOR
Barnes Retina Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Macula-Retina-Vitreous Service, Midwest Eye Institute
Indianapolis, Indiana, United States
Barnes Retina Institute
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ramaiya KJ, Blinder KJ, Ciulla T, Cooper B, Shah GK. Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome. Ophthalmic Surg Lasers Imaging Retina. 2013 Jan-Feb;44(1):17-21. doi: 10.3928/23258160-20121221-07.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FVF4145s
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.